Journal of Psychiatric Research
June 1, 2026
Ludovic Samalin, Maud Rothärmel, Lila Mekaoui et al.
In patients with treatment-resistant depression (TRD), the efficacy and tolerance of intranasal esketamine (ESK) spray, alone or combined with oral antidepressants, has been supported by clinical trials and observational studies. The French real-world ESKALE study assessed the benefit of ESK in 157 patients with TRD. In this post-hoc analysis of the ESKALE study we aimed to describe the...
Asian Journal of Psychiatry
June 1, 2026
Fabiola Raffone, Filippo Mazzoni, Arianna De Ciechi et al.
3 citations
Suicidal ideation and deliberate self-harm are frequent and persistent in treatment-resistant depression (TRD), particularly when comorbid borderline personality disorder (BPD) is present. Real-world evidence on antisuicidal outcomes during intranasal esketamine in this population remains limited. In this multicentre prospective observational study, 90 outpatients with TRD received intranasal...
medRxiv Preprint Server
May 31, 2026
Yves Martins Varela, Patrícia Cavalcanti-Ribeiro, Geovan Menezes de Sousa et al.
preprint
Background Ketamine has emerged as an effective rapid-acting treatment for treatment-resistant depression (TRD), producing significant antidepressant effects within hours of administration. Given ketamine’s capacity to induce states of heightened neuroplasticity and psychological openness, psychotherapy may represent a meaningful complement to its pharmacological effects — facilitating...
Research Square
May 27, 2026
Tychique T. Wasolua, Tanner J. Bommersbach, Roger S McIntyre et al.
preprint
Abstract Ketamine and esketamine are increasingly used as rapid-acting antidepressants, yet concerns remain regarding potential structural neurotoxicity, particularly with chronic or high-dose exposure. Despite expanding clinical use, no comprehensive systematic review has integrated neurotoxicity evidence across preclinical and human studies while formally evaluating methodological quality....
Therapeutic Advances in Psychopharmacology
May 22, 2026
Liliana Patarroyo-Rodriguez, Vanessa K. Pazdernik, Jennifer L. Vande Voort et al.
Background: Ketamine and esketamine ((es)ketamine) rapidly reduce depressive symptoms and suicidal ideation (SI) in treatment-resistant depression (TRD), but whether early SI improvement during the acute phase of the treatment predicts reduced suicide-associated emergency department (SAED) visits over the longer term remains unclear. Objectives: To examine whether early improvements in SI,...
Therapeutic Advances in Psychopharmacology
May 19, 2026
correction
[This corrects the article DOI: 10.1177/20451253261437597.].
Behavioral Sciences
May 14, 2026
Fabiola Raffone, Carlo Ignazio Cattaneo, Enrico Pessina et al.
Trauma-related autobiographical memories can manifest as involuntary, vivid, emotionally charged intrusions that perpetuate avoidance, negative emotions, and functional impairment. While these memories are central to post-traumatic stress disorder (PTSD), they also occur across diagnoses and are often reported in depressive disorders, including treatment-resistant depression (TRD). Although...
Fortschritte der Neurologie · Psychiatrie
May 13, 2026
Cornelius Schüle, Anna Sobieraj, Helena Rogg
1 citation
Abstract: Esketamine is an NMDA receptor antagonist and was approved as a nasal spray in March 2019, initially in the USA and then in December 2019 in Europe, as an adjunct to antidepressant pharmacotherapy for the treatment of treatment-resistant major depression or for rapid symptom reduction in psychiatric emergency situations in patients with major depression. In addition, esketamine nasal...
Journal of Pre-Clinical and Clinical Research
May 12, 2026
Bartłomiej Kosiarski, A. Skrzypek, Patrycja Markowicz et al.
Rapid-acting interventions in treatment-resistant depression – a comparative review of
Psychiatry Research
May 12, 2026
Isis Lunsky, Gilmar Gutierrez, Xena Wang et al.
Postpartum Depression (PPD) is a common condition with serious consequences for both mother and baby if left untreated. Currently, few effective strategies exist for prevention of PPD. Ketamine and Esketamine are rapid acting and potent antidepressants, and emerging evidence is showing promising results for PPD. This review searched the MEDLINE, CINAHL, PsycINFO, EMBASE, and Cochrane databases,...